Dare Bioscience (NASDAQ:DARE) Posts Quarterly Earnings Results

Dare Bioscience (NASDAQ:DARE – Get Free Report) posted its quarterly earnings results on Monday. The biotechnology company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.05), Zacks reports. Dare Bioscience had a negative return on equity of 748.30% and a negative net margin of 803.80%.

Dare Bioscience Price Performance

Dare Bioscience stock traded down $0.07 during mid-day trading on Monday, hitting $0.58. 184,649 shares of the company’s stock traded hands, compared to its average volume of 374,677. The firm has a 50 day simple moving average of $0.73 and a two-hundred day simple moving average of $1.51. Dare Bioscience has a fifty-two week low of $0.58 and a fifty-two week high of $3.78. The stock has a market cap of $11.49 million, a price-to-earnings ratio of -0.83 and a beta of 1.11.

Analysts Set New Price Targets

Several research firms have recently commented on DARE. UBS Group set a $1.00 price objective on Dare Bioscience in a report on Monday, September 14th. Benchmark reissued a “buy” rating on shares of Dare Bioscience in a research note on Monday, August 17th. Ladenburg Thalmann & Co. Inc. began coverage on shares of Dare Bioscience in a report on Monday, October 26th. They set a “buy” rating and a $2.00 target price on the stock. HC Wainwright reaffirmed a “buy” rating on shares of Dare Bioscience in a research report on Monday, August 17th. Finally, Weiss Ratings lowered shares of Dare Bioscience from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, September 16th. Three equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Dare Bioscience presently has an average rating of “Moderate Buy” and a consensus price target of $5.00.

View Our Latest Stock Analysis on Dare Bioscience

Dare Bioscience Company Profile

(Get Free Report)

Daré Bioscience is a clinical-stage biopharmaceutical company focused on developing therapies and products for women’s health. Its work spans areas including contraception, vaginal health and sexual health, with an emphasis on addressing conditions and needs that have had limited treatment options. The company’s product candidates include Ovaprene, a hormone-free, monthly-use vaginal contraceptive, and investigational treatments for conditions such as female sexual arousal disorder. These candidates remain in development and are not approved for general use.

Featured Stories

Earnings History for Dare Bioscience (NASDAQ:DARE)

Receive News & Ratings for Dare Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dare Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.